Special Issue

Nanomaterial Complexes Used in Cancer Therapies: Opportunities and Challenges

Message from the Guest Editor

Conventional cancer therapeutics have limited effectiveness and low selectivity due to their poor solubility, inadequate biodistribution, low stability, and high toxicity. The most promising path to overcoming these limitations is through the use of smart nanomaterials. In recent years, quantum dots, metallic nanoparticles, liposomes, dendrimers, micelles, and polymeric nanoparticles have been used to engineer the composition, synthesis methods, size, morphology, and surface chemistry of therapeutic drugs. However, some limitations, including toxicity, the uniform size/shape of nanomaterials, and limited biocompatibility with specific cell membranes, need to be resolved. Today, studies mainly use universal nanoparticles that are able to incorporate drugs and genes simultaneously or separately and allow their release spatially or temporally. Overall, stimuli-responsive smart nanomaterials hold great potential for improving the efficacy of cancer diagnosis and therapy, and new strategies should be developed to address the challenges in designing precise nanomedicines.

Guest Editor

Dr. Ruizhuo Ouyang

School of Materials and Chemistry, University of Shanghai for Science and Technology, Shanghai, China

Deadline for manuscript submissions

closed (25 October 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/203313

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

